Anne-Marie Malfait to Endopeptidases
This is a "connection" page, showing publications Anne-Marie Malfait has written about Endopeptidases.
Connection Strength
1.757
-
The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):130-134.
Score: 0.678
-
Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys. 2008 Oct 01; 478(1):43-51.
Score: 0.311
-
Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol. 2008 Feb; 9(1):16-23.
Score: 0.301
-
Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002 Jun 21; 277(25):22201-8.
Score: 0.202
-
Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models. J Orthop Res. 2011 Apr; 29(4):516-22.
Score: 0.091
-
An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: Use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem. 2010 Nov 15; 406(2):113-23.
Score: 0.089
-
Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem. 2009 Sep 04; 284(36):24185-91.
Score: 0.083